Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma
Top Cited Papers
- 10 April 2009
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 27 (11), 1781-1787
- https://doi.org/10.1200/jco.2008.16.1513
Abstract
Purpose In lymphoma, [18F]fluorodeoxyglucose positron emission tomography (FDG-PET) is routinely used for initial staging, early evaluation of treatment response, and identification of disease relapse. However, there are no prospective studies investigating the value of serial FDG-PET over time in patients in complete remission. Patients and Methods All patients with lymphoma who achieved the first complete remission were prospectively enrolled onto the study and scheduled for serial FDG-PET scans at 6, 12, 18, and 24 months; further scans were then carried out on an annual basis. Overall, the population included 421 patients (160 patients with Hodgkin's lymphoma [HL], 183 patients with aggressive non-Hodgkin's lymphoma [NHL], and 78 patients with indolent follicular NHL). All patients had a regular follow-up evaluation, including complete clinical and laboratory evaluation, and final assessment of any suspect FDG-PET findings using other imaging procedures (computed tomography [CT] scan) and/or biopsy an...Keywords
This publication has 32 references indexed in Scilit:
- Revised Response Criteria for Malignant LymphomaJournal of Clinical Oncology, 2007
- Predictive Role of Positron Emission Tomography in the Outcome of Patients with Follicular LymphomaClinical Lymphoma Myeloma and Leukemia, 2007
- FDG-PET in the clinical management of Hodgkin lymphomaCritical Reviews in Oncology/Hematology, 2004
- Frequent Impact of [18F]Fluorodeoxyglucose Positron Emission Tomography on the Staging and Management of Patients with Indolent Non-Hodgkin's LymphomaClinical Lymphoma, 2003
- PET for staging of Hodgkin's disease and non-Hodgkin's lymphomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2003
- Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphomaAnnals of Nuclear Medicine, 2002
- Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin’s disease and non-Hodgkin’s lymphomaAmerican Journal Of Medicine, 2002
- Positron Emission Tomography for the Staging of Hodgkin's Lymphoma - Increasing the Body of Evidence in Favor of the MethodActa Oncologica, 2002
- Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's diseaseAnnals of Hematology, 2001
- 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphomaCancer, 2001